SEC Form 4 · accession 0000880771-16-000193
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy T Chang
Director
Period of report
Sep 29, 2016
Accepted (ET)
Sep 29, 2016 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 29, 2016 | M | 7,648 | $5.10 | A | 36,667 | D | |
| Common Stock | Sep 29, 2016 | M | 33,333 | $5.22 | A | 70,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $5.10 | Sep 29, 2016 | M | 7,648 | D | — | Jun 12, 2024 | Common Stock | 7,648 | 0 | D |
| Non-Qualified Stock Option (right to buy)F1,F3 | $5.22 | Sep 29, 2016 | M | 33,333 | D | — | Jun 17, 2023 | Common Stock | 33,333 | 0 | D |
Explanation of responses
- F1Granted under the Issuer's 2005 Equity Incentive Plan.
- F2Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.
- F3Shares will become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.